// App-Quantinova.ai

PO‐089 : The impact of maintenance lenalidomide and depth of response on the mutational status of the myeloma clone from presentation to relapse

Researchers

Presenter

  • J Jones

Principal Investigators

  • S Chavan

  • C Pawlyn

  • L Melchor

  • D Cairns

  • D Johnson

  • B Walker

  • C Wardell

  • D Begum

  • S Ellis

  • C Smith

  • A Sherborne

  • A Price

  • G Cook

  • M Jenner

  • N Russell

  • M Drayson

  • R Owen

  • F Davies

  • M Kaiser

  • W Gregory

  • G Jackson

  • M Greaves

  • G Morgan

Medical Centers

  • Molecular Pathology, Institute of Cancer Research, Sutton, United Kingdom

  • University of Arkansas, Myeloma Institute, Little Rock, United States

  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research

  • University of Leeds, Leeds, UK

  • University of Southampton, Southampton, UK

  • Nottingham University hospital, U.K., Nottingham,

  • Clinical Immunology, School of Immunity & Infection, University of Birmingham, Birmingham, United Kingdom

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

  • Centre for Evolution and Cancer, The Institute of Cancer Research, London SW7 3RP, UK, London, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Interferon regulatory factor 4

Drug/Treatment

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Randomized

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved